Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00515-6/fulltext?dgcid=hubspot_update_feature_updatealerts_lanonc&utm_campaign=update-lanonc&utm_medium=email&_hsmi=282328213&_hsenc=p2ANqtz--oBleHbpZ4SFze_jT3n8LgecYtmHQ-dubEIDDKpqRMckoIE8UuTsjha6ldoaun3EApGFqtLAa5C9GbhGnT5c8ETxeCqg&utm_content=282312127&utm_source=hs_email